ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

16 Tips from 16 Years Sick

Fibromyalgia Fare Fit for All Seasons

Tangerine Oil: A Citrusy Essential Oil With Well-Rounded Uses

New Study Shows Artificial Sweeteners Lead to Diabetes

Essential Oils — An Effective and Healthy Option to Treat Headaches

Antioxidant treatment could halt neurodegeneration in early Parkinson's

Higher vitamin D levels associated with less severe disease in NAFLD patients

Krill Oil: Make This Omega-3 Supplement Part of Your Health Regimen

How zinc helps fight esophageal cancer

Everything You Need to Know About Black Cohosh

 
Print Page
Email Article

Results of Fibromyalgia Syndrome Phase II Trial Announced

  [ 329 votes ]   [ Discuss This Article ]
By ImmuneSupport Staff • www.ProHealth.com • March 17, 2000


SUMMARY: A study reports promising results using 50-IU IFN alpha lozenges as an effective treatment for fibromyalgia.

ABSTRACT:
The three-month study, involving 89 Fibromyalgia patients at four clinical sites around the United States, was designed to measure the effectiveness of low doses of orally administered interferon-alpha (IFN alpha) in relieving morning stiffness of joints, a significant problem for fibromyalgia sufferers.

The double-blinded, placebo-controlled test was the second in a series of trials that, if successful, would lead to U.S. Food & Drug Administration (FDA) approval of the new treatment regimen. Patients participating in the study were divided into three groups, and each individual was given three lozenges per day. The three lozenges given to members of the first group contained 50 international units (IU) of IFN alpha each, while the second group was given one 50 IU IFN alpha lozenge and two placebos. Members of the final group received three placebos. All three groups reported a reduction in morning stiffness, but across the entire study, the improvement was most pronounced in those taking one 50 IU lozenge of IFN alpha per day. However, the result did not reach statistical significance relative to the controls, nor did increasing the dosage to three IFN alpha lozenges per day improve the results.

All 89 participants were also given a low dose of the anti-depressant drug, amitriptyline, which they began taking one month prior to the start of the IFN alpha trial and continued throughout the three-month study. Dr. Philip C. Fox, Director of Research and Development for Amarillo Biosciences, said addition of the amitriptyline was deemed necessary so the patients would not have to tolerate a four-month period without therapy. However, he also noted that use of the amitriptyline complicated the analysis and interpretation of the study results.

"In an effort to isolate the effects of the amitriptyline on the stiffness results, we looked at the responses of patients during the first month of the study, when they were receiving only amitriptyline," said Dr. Fox. "Patients who did not worsen during the first month's treatment with amitriptyline went on to demonstrate a significant reduction in morning stiffness (p=0.0035) when they took the 50-IU IFN alpha lozenges once a day for three months compared with a placebo. However, those patients who reported worsening of their morning stiffness during the first month showed no benefit during the subsequent three months of IFN alpha treatment."

The reduction in morning stiffness found in this study was consistent with results from an earlier six-week blinded trial except this test showed a more positive response in the placebo-treated group. (Note: It is well documented in such studies that patients taking placebos tend to report at least some improvement even though they are receiving no active drug.) Interestingly, though, this "placebo effect" varied significantly from site to site. At one of the four locations, for example, 20 patients were treated and those receiving one 150 IU lozenge per day reported results consistent with one-a- day groups throughout the study. However, placebo patients at this same site noted only minimal improvement relative to those at the other sites.

Fox also said that the search for relief for fibromyalgia sufferers, estimated to number between 4 million and 7 million in the U.S. alone, is important because current therapeutic options are inadequate and no medication has been specifically approved by the FDA for treatment. Rheumatologists typically prescribe pain relievers, sleeping aids, anti-depressants and exercise for patients with the syndrome.



Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength Energy NADH™ 12.5mg Ultra EPA  - Fish Oil


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

The Curcumin Revolution: 'Golden' Ticket to Better Health The Curcumin Revolution: 'Golden' Ticket to Better Health
Prepare Yourself for Cold & Flu Season Prepare Yourself for Cold & Flu Season
The Fast-Acting Solution for Healthy Digestive Function The Fast-Acting Solution for Healthy Digestive Function
Could a B-12 Deficiency Be Causing Your Symptoms? Could a B-12 Deficiency Be Causing Your Symptoms?
Vital Molecule Increases Cellular Energy and Improves Cognitive Function Vital Molecule Increases Cellular Energy and Improves Cognitive Function

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map